Follow-up of an automated insulin pump in adults with type 1 diabetes
Observes long-term use of an automated insulin device in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Steno780G Follow-up Study
Key facts
- Where
- Herlev, DenmarkSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes who took part in the earlier Steno780G study. It follows how an automated insulin pump works over several years.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes. No further stage is stated.
- Earlier treatment
- Must have taken part in the Steno780G study before.
Main reasons for not taking part
- Not following the key study procedures, as judged by the investigator.
Read by machine on 9 November 2026.
Where in Denmark
- Steno Diabetes Center CopenhagenHerlev, DenmarkNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Steno Diabetes Center Copenhagen
- Trial code
- NCT07474155
- Record updated
- 16 March 2026
- Original description
Automated insulin delivery systems, also known as closed-loop systems, have shown to improve TIR, TAR, and TBR compared with insulin pump and CGM systems that cannot automatically dose insulin. Only few studies have described long-term use of AID systems over several years. Real-world studies suggest that the beneficial effects of AID systems on glycemic outcomes are sustained over time; however, a modest increase in body weight has been observed in some users, raising concerns about the metabolic trade-offs of improved glycemia. We aim to explore wether the improvements in glycemic outcomes and treatment satisfaction achieved with AID systems remain stable over multiple years, and secondly, if long-term treatment with AID systems may be associated with an increase in body weight.Read full original descriptionShow less
Advanced Hybrid Closed-Loop Treatment in Adults With Type 1 Diabetes Not Meeting Glycaemic Targets - The Steno780G Follow-up Study
Automated insulin delivery systems, also known as closed-loop systems, have shown to improve TIR, TAR, and TBR compared with insulin pump and CGM systems that cannot automatically dose insulin. Only few studies have described long-term use of AID systems over several years. Real-world studies suggest that the beneficial effects of AID systems on glycemic outcomes are sustained over time; however, a modest increase in body weight has been observed in some users, raising concerns about the metabolic trade-offs of improved glycemia. We aim to explore wether the improvements in glycemic outcomes and treatment satisfaction achieved with AID systems remain stable over multiple years, and secondly, if long-term treatment with AID systems may be associated with an increase in body weight.
Inclusion: Previous participation in the Steno780G study.
Exclusion: Lack of compliance with key study procedures at the discretion of the investigator.